Compare TG Therapeutics Inc (TGTX) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Western Alliance Bancorporation — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Western Alliance Bancorporation trades at $74.27 (market cap $8.24B). The key difference: TG Therapeutics Inc and Western Alliance Bancorporation are close in size by market cap, and Western Alliance Bancorporation pays a 2.23% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Western Alliance Bancorporation for 3 Days on average.
| TGTX | WAL | |
|---|---|---|
Market Cap | $8.16B | $8.24B |
Volume | 1,735,121 | 1,387,161 |
Sector | Health | Financials |
52-Week High | $59.06 | $96.08 |
52-Week Low | $26.94 | $66.70 |
Typical Hold Time | 16 Days | 3 Days |
Enterprise Value | $8.37B | $9.76B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% on the day, amid a bearish technical signal despite a neutral oscillator reading. The company reported strong revenue growth, with 2025 revenue at $616.29M and net income of $447.18M, though recent quarterly EPS misses and a negative net cash flow of $100.70M in 2025 highlight operational challenges. Positive news includes BRIUMVI capturing significant market share and institutional buying interest.
The outlook is mixed; robust analyst consensus (84.62% buy ratings) and a $80.50 price target suggest upside, but risks include ongoing litigation, earnings volatility, and high valuation multiples. Key catalysts are subcutaneous BRIUMVI data and potential acquisition interest, though execution risks remain.
Western Alliance Bancorporation (WAL) trades at $75.50, up 1.55% today, with strong analyst support (79% buy ratings) and a consensus price target of $85.09. The stock shows bearish technical signals but maintains solid fundamentals with a P/E of 8.52 and net income margin of 25.43%. Recent Q2 2026 earnings matched expectations at $2.36 EPS, while revenue growth continues with 2026 projections at $3.9B.
WAL presents a compelling value opportunity with attractive valuation multiples and strong profitability metrics, though technical indicators suggest near-term caution. The bank's strategic initiatives, including the WA VenueX platform launch and institutional investment growth, support long-term upside potential. Key risks include regulatory changes and interest rate sensitivity affecting net interest income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
